Atlas and OrbiMed back Boston's Kyn in $49M round to pursue immunometabolism therapies
Boston biotech Kyn Therapeutics has raised $49 million in a Series A round to advance its immunometabolism therapies to treat cancer.
The money comes from Atlas Venture and OrbiMed — both repeat investors who first funded the company during its launch last March.
Kyn is led by an Atlas entrepreneur-in-residence Mark Manfredi, who was previously chief scientific officer at Raze Therapeutics (also an Atlas-funded startup). Raze raised a $24 million Series A in 2014, but the company appears to have wound down pretty quickly. The website is no longer active, and Manfredi said Raze still has some assets and collaborations, but no longer employs anyone. Atlas’ Bruce Booth says the underlying cancer metabolism biology was too complicated to warrant further investment. Before Raze, Manfredi was VP of oncology biology at Takeda.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.